LifeSci Capital analyst Sam Slutsky initiated coverage of Immunic (IMUX) with an Outperform rating and $56 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 4/30/26?
- Immunic price target adjusted to $22 from $5 at H.C. Wainwright
- Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/29/26?
- Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/28/26?
- Immunic Appoints Veteran Neurology Leader as Chief Medical Officer